Orphan diseases are those where there re very few patients in the world for the specific diseases and hence unviable. One of the orphan diseases we have been championing is Mucopolysaccharidosis, which is inflammation of the bones leading to dwarfism.
We have led the initiative by sponsoring our medicine for research at prestigious Mt. Sinai Hospital in New York, for a new medicine at cost of less than USD 5000/year as against the present costs of hormone therapy running into USD 300,000/year.